Page last updated: 2024-12-08

dexefaroxan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dexefaroxan: an alpha(2)-adrenoceptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID208820
CHEMBL ID1357517
SCHEMBL ID194978
MeSH IDM0420433

Synonyms (21)

Synonym
NCGC00015410-01
NCGC00024793-01
lopac-e-3263
tocris-0792
(+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline
143249-88-1
2-[(2r)-2-ethyl-3h-1-benzofuran-2-yl]-4,5-dihydro-1h-imidazole
dexefaroxan
f751mo69ev ,
2-imidazoline, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-, (+)-(r)-
dexefaroxan [inn]
unii-f751mo69ev
NCGC00015410-02
CHEMBL1357517
1h-imidazole, 2-((2r)-2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-
(+)-efaroxan
1h-imidazole, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-, (r)-
2-((2r)-2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro-1h-imidazole
SCHEMBL194978
l-0046
Q27277745

Research Excerpts

Treatment

Dexefaroxan treatment also enhanced the number and complexity of the dendritic arborizations of polysialated neural cell adhesion molecule-positive neurons.

ExcerptReferenceRelevance
"In dexefaroxan-treated devascularized rats, increases in NGF protein levels (2-fold) and immunoreactivity were maintained in both the cortex and NbM over the entire 28-day postoperation period; these increases were coincident with changes in functional markers characteristic of NGF's actions, including increases in choline acetyltransferase (ChAT), p75 and TrkA immunoreactivities, and a preservation of NbM cholinergic cell numbers."( In vivo upregulation of endogenous NGF in the rat brain by the alpha2-adrenoreceptor antagonist dexefaroxan: potential role in the protection of the basalocortical cholinergic system during neurodegeneration.
Colpaert, F; Debeir, T; Ferrario, J; Marien, M; Prigent, A; Raisman-Vozari, R; Rizk, P, 2004
)
1.06
"Dexefaroxan treatment also enhanced the number and complexity of the dendritic arborizations of polysialated neural cell adhesion molecule-positive neurons."( The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells.
Colpaert, F; Debeir, T; Marien, M; Raisman-Vozari, R; Rizk, P; Ruberg, M; Salazar, J, 2006
)
1.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NFKB1 protein, partialHomo sapiens (human)Potency19.95260.02827.055915.8489AID895; AID928
ThrombopoietinHomo sapiens (human)Potency10.00000.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency18.85410.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency15.84890.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
pyruvate kinase PKM isoform bHomo sapiens (human)Potency0.02002.511912.262825.1189AID954; AID958
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (73.33)29.6817
2010's2 (13.33)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.66 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]